BVS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BV

Mkt Cap

$909.0M

Volume

254.86K

Next Earnings

November 3rd

Loading chart

BV

BVSBioventus Inc. Class A Common Stock

BVS

Pay with—

Available Balance0.00

BV

Mkt Cap

$943.3M

Volume

254.86K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare ConferenceBioventus Inc. announced that Mark Singleton, Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026. The presentation will be webcast live and available for replay on the company's investor website.GlobeNewswire Inc. · Jun 2, 2026

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItConexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) submission in early 2027 and holds issued patents across major markets with no royalty obligations.Benzinga · May 22, 2026

Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor IntelligenceThe global orthobiologics market is projected to grow from USD 6.68 billion in 2025 to USD 9.52 billion by 2031, with a CAGR of 6.17%. Growth is driven by rising osteoarthritis cases, sports-related injuries, and advancements in regenerative therapies including stem cell therapy and platelet-rich plasma treatments. North America leads the market while Asia-Pacific is the fastest-growing region.GlobeNewswire Inc. · Mar 12, 2026

Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased LiquidityBioventus secured a new $400 million credit agreement, replacing its previous 2019 credit facilities, which reduces interest expenses and increases liquidity from $40 million to $100 million in revolving credit.GlobeNewswire Inc. · Aug 4, 2025

Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market InsightsThe global intramedullary nail market is expected to grow rapidly, driven by the rising incidence of bone fractures, particularly among the aging population, and advancements in surgical techniques. However, the market faces challenges such as high procedural costs, the need for skilled professionals, and competition from alternative fixation devices.GlobeNewswire Inc. · Apr 10, 2025

Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034The global osteoarthritis therapeutics market is expected to grow from USD 9.91 billion in 2024 to USD 24.34 billion by 2034, driven by the rising prevalence of osteoarthritis and technological advancements in surgical treatments. Europe and Asia Pacific are the key regional markets.GlobeNewswire Inc. · Nov 26, 2024

U.S. Osteoarthritis Injectables Market Analysis 2024-2030: Rising Prevalence of Osteoarthritis & Increase in R&D Activities for Injectable Drug Developments Spurs GrowthThe U.S. osteoarthritis injectables market is expected to grow significantly due to the rising prevalence of osteoarthritis, the growing geriatric population, and increased R&D activities for injectable drug development.GlobeNewswire Inc. · Oct 4, 2024

First September Gains in 5 Years? Buy 3 Breakout Stocks NowThe article discusses how September has historically been a weak month for the stock market, but this year the S&P 500, Dow, and Nasdaq have gained over 1% so far, breaking a 5-year trend. The author recommends buying three breakout stocks that could take advantage of the broader market's upward movement: Bioventus (BVS), Great Lakes Dredge & Dock (GLDD), and AxoGen (AXGN).Benzinga · Sep 24, 2024

Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR ReportThe global pseudarthrosis treatment market is expected to grow at a CAGR of 4.6% from 2024 to 2034, driven by advancements in biocompatible materials and positive government reimbursement programs. North America and South Asia & Pacific are the key regions driving market growth.GlobeNewswire Inc. · Sep 5, 2024

Corcept Shares Rise More Than 45% in Six Months: Here's WhyCorcept Therapeutics' (CORT) shares have gained over 45% in the past six months, driven by strong performance of its sole-marketed drug Korlym and progress in the development of its lead pipeline candidate relacorilant for treating Cushing's syndrome.Benzinga · Sep 3, 2024

to start trading

BV

BVSBioventus Inc. Class A Common Stock

BVS

Pay with—

Available Balance0.00

Your PositionYou don't own any BVS yet.

Related Tickers

Earnings